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Long non-coding RNAs (lncRNAs) are defined as a class of nonprotein-coding transcripts greater than 200 nucleotides in 
length, which have diverse functions in development and diseases including hematopoiesis. Recent advances have revealed 
that lncRNAs regulate hematopoietic development at almost every stage, including differentiation of the myelocyte, lympho-
cyte, and erythrocyte. Abnormal regulation of the lncRNAs may block aspects of blood development, which can lead to dif-
ferent types of hematopoietic disorders. These findings highlight the role of lncRNAs as potential therapeutic tools in malig-
nant hematopoiesis. In this review, we summarize recent progress in the study of functional lncRNAs associated with blood 
development, as well as dysregulated lncRNAs involved in diverse blood diseases by interacting with crucial susceptibility 
genes in different pathways. In addition, we discuss genome-wide studies on lncRNAs, which are helpful for genome screen-
ing and in-depth functional study of lncRNAs associated with blood development and disease. 
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Long nonprotein-coding RNAs (lncRNAs) are generally 
defined as a category of nonprotein-coding transcripts more 
than 200 nucleotides in length. lncRNA genes cover ap-
proximately 90% of the human genome [14]. In recent 
years, it has become evident that lncRNAs are involved in a 
variety of cell processes [13,5], particularly during devel-
opment and diseases [1,2,6]. Like microRNAs (miRNAs),  
a well-studied class of small nonprotein-coding RNAs, 
lncRNAs have also been shown to be highly involved in 
hematopoietic development, including proliferation, differ-
entiation, and apoptosis of hematopoietic stem cells, as well 
as progenitors and precursors of multi-lineage mature blood 
cells, which include erythrocytes, megakaryocytes, myelo-
cytes (monocyte, macrophage and neutrophil), and lym-
phocytes (B-cell and T-cell) [715]. Several findings sug-
gest that dysregulation of the lncRNAs can lead to abnormal 
modulation of multiple cellular pathways, and result in var-
ious hematological malignancies, including lymphoma, 
multiple myeloma and leukemia, which together account for 
nearly 7% of all cancer diagnoses [12,1619]. Dysregula-
tion of the lncRNAs can also lead to anemia, which is the 
most common disorder of the blood system [14]. These in-
volvements suggest the potential clinical relevance of 
lncRNAs in the diagnosis, prognosis, and therapy of these 
blood diseases. 
lncRNAs regulate gene transcription and translation 
through different mechanisms, including interaction with 
RNA-binding proteins to reduce the translation activity of 
mRNA, recruiting protein complex to epigenetically regu-
late gene expression, and competition with mRNAs for 
shared miRNAs to act as post-transcriptional modifiers  
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[13,20]. Although the mechanisms underlying the function 
of most lncRNAs are not fully understood, functional anno-
tation has provided a complex regulation theory and classi-
fication for lncRNAs [21]. Importantly, accumulating evi-
dence suggests that lncRNAs have multiple functions in 
normal and malignant hematopoiesis [1114,16,17], and 
these clues help better understand the biology of hemato-
poiesis and blood diseases. In this review, we summarize 
the recent progress in our understanding of some of the 
mechanisms behind the involvement of lncRNAs in blood 
development and blood diseases through their function in 
modulating crucial susceptibility genes in diverse pathways. 
We also discuss the use of genome-wide lncRNA studies 
for screening potential biomarkers or therapeutic targets in 
blood disease treatment. 
1  lncRNAs involved in normal hematopoiesis 
Unlike mRNAs and miRNAs, lncRNAs are poorly con-
served among species; however, a proportion of human 
lncRNAs share similar functions with murine orthologs, 
such as Xist, H19 and Tmevpg1 [4]. Therefore, several   
studies that focus on these lncRNAs in mouse model also 
provide important information for a better understanding of 
hematopoiesis. lncRNA expression levels in normal hema-
topoiesis have been studied in both murine and human 
blood cells, and a number of lineage-specific expressed 
lncRNAs are considered as spatiotemporal regulators of 
blood development [11,14] (Figure 1, left). 
1.1  Erythroid development-related lncRNAs 
Erythroid development, which is the process that produces 
red blood cells, is essential for the circulation system. A 
murine lncRNA, lincRNA-EPS, is a long intergenic 
non-coding RNA that was found to be highly specific to 
terminally differentiating erythroid cells [14]. The expres-
sion of lincRNA-EPS was strongly induced when erythroid 
precursors begin to synthesize hemoglobin and other line-
age-specific proteins, while the inhibition of lincRNA-EPS 
was shown to block differentiation and promote apoptosis 
of erythroid progenitors, which might be related to the 
proapoptotic gene Pycard [14]. Briefly, lincRNA-EPS 
might bind to the Pycard locus and recruit transcriptionally 
repressed complexes to suppress the expression of Pycard. 
Reduced Pycard expression may not be enough to promote 
cell death by activating intercellular caspases, and thus 
normal erythroid differentiation is induced. Although the 
protein components associated with lincRNA-EPS in regu- 
lating erythroid differentiation are unclear, lincRNA-EPS is 
the first lncRNA to be related to red blood cells; however, 
whether this lncRNA is evolutionarily conserved in human 
is still unknown. Because anemia is generally caused by a 
lack of red blood cells or hemoglobin, lncRNAs that are 
involved in erythropoiesis could potentially be exploited for 
the treatment of anemia and other blood diseases.  
1.2  Myeloid differentiation-related lncRNAs 
Myelocytes are important in the innate immune system, and 
abnormal proliferation and differentiation of myeloid cells 
are associated with acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML) and myelodysplastic syndrome 
(MDS). Eosinophil granule ontogeny (EGO) is a myeloid 
progenitor differentiation-related lncRNA, which is tran-
scribed antisense to an intron of inositol triphosphate re-
ceptor type 1 (ITPR1). EGO is highly expressed in human 
bone marrow and in mature eosinophils [11]. Following 
interleukin-5 (IL-5) stimulation, EGO transcript levels in-
creased rapidly in both CD34+ hematopoietic progenitors 
purified from mononuclear cord blood and bone marrow 
mononuclear cells, and then returned to basal level within 
72 h. It was proposed that EGO can affect myeloid devel-
opment by regulating the expression of eosinophil genes, 
including major basic protein (MBP) and eosinophil derived 
neurotoxin (EDN), in developing CD34+ hematopoietic 
progenitors [11]. Because EGO maintains a high expression 
level in the CD34+ erythroleukemic cell line TF-1, and a 
variety of blood diseases are caused by abnormalities of 
hematopoietic progenitor differentiation, especially myeloid 
progenitor differentiation, dysregulated or mutant EGO 
transcripts might serve as a potential etiology of blood dis-
eases, such as erythroleukemia, myeloproliferative disorder, 
and myeloid leukemia [11]. 
Another lncRNA, HOTAIRM1, has been identified as an 
essential regulator of retinoic acid-induced myeloid cell 
differentiation [12]. It was found that the expression levels 
of HOTAIRM1 showed a positive correlation with its 
neighboring gene, HOXA1, and knock-down of HOTA- 
IRM1 prevented the expression of HOXA1, HOXA4, CD11b, 
and CD18, which are essential transcription factors and an-
tigens in myeloid cell differentiation. Moreover, the murine 
Hotairm1 was found to interact with the chromatin remodel-
ing complexes, polycomb repressor complex 1 (PRC1) and 
PRC2 [22], which implies that HOTAIRM1 might maintain 
myeloid differentiation epigenetically in both human and 
murine. Because retinoic acid is an important drug in myeloid 
leukemia treatment [23], HOTAIRM1 might serve as a pivot-
al therapy target for some leukemia subtypes. 
1.3  Lymphoid differentiation and immune-related 
lncRNAs 
A number of lncRNAs are involved in the development and 
function of T-cells and B-cells, and because of the essential 
role of these lymphocytes in the adaptive immune system, 
these lncRNAs are generally involved in immune reactions. 
Non-coding RNA repressor of NFAT (NRON) is present 
in a cytoplasmic RNA-protein scaffold complex that in-  
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Figure 1  Normally expressed and dysregulated lncRNAs during hematopoiesis. Normally expressed lncRNAs ensure the normal differentiation of hema-
topoietic stem cells into erythrocytes (lincRNA-EPS), myelocytes (EGO, HOTAIRM1) and lymphocytes including B-cells (BIC) and T-cells (NRON, 
TMEVPG1 and Thy-ncR1), and these lncRNAs contribute to maintaining normal hematopoiesis. Dysregulated lncRNAs may disorder the biology of hema-
topoietic cells. For example, dysregulated HOTAIR, HOTAIRM1, Mira, or Linc-HOXA1 leads to the deregulation of HOX genes, mis-expressed ANRIL 
leads to disordered cell cycles, abnormal expression of MEG3, PVT1, DLEU1 or DLEU2 results in activation of oncogenes and inhibition of tumor sup-
pressors, and dysregulated H19 and XIST leads to abnormal imprinting and X-aneuploidies, respectively. These disorders triggered by dysregulated 
lncRNAs result in blood diseases. 
cludes phosphorylated NFAT1, a Ca2+-regulated transcrip-
tion factor that controls gene expression in T-cell differenti-
ation. Knock-down of NRON increases NFAT dephosphor-
ylation, nuclear import (exclusively after stimulation), and 
production of NFAT-dependent cytokines [24]. Moreover, 
because lymphocytes are essential for the adaptive immune 
system, lncRNAs that are associated with lymphoid differ-
entiation must also have an immune-related function. An-
other T-cell differentiation-related lncRNA, Thy-ncR1, is 
expressed specifically in cell lines derived from stage III 
immature T-cells, and might participate in T-cell selection 
and maturation by controlling the degradation of MFAP4 
mRNA [13]. In addition, in the stage III immature T-cells, 
the CD1 gene cluster, which neighbors Thy-ncR1, is also 
activated specifically. Although it is unclear whether the 
expression of Thy-ncR1 is linked mechanistically to the 
activation of the CD1 gene cluster, the co-expressed phe-
nomenon of the CD1 gene cluster and Thy-ncR1 implies a 
potential synergistic effect of CD antigens and lncRNAs 
during T-cell selection and maturation [13]. Besides, 
TMEVPG1, a lncRNA studied in both murine and human, 
is located adjacent to the interferon-g (IFNG) gene, and 
induces IFN-g synthesis in a series of T-cells [25,26]. Con-
sidering the importance of IFN-g in T-cell selection, matu-
ration and immunization, TMEVPG1 plays multiple roles in 
lymphopoiesis, including driving the Th1 cell differentia-
tion program [25] and increasing Theiler’s virus persistence 
of activated CD8+ T-cells [26]. Further studies have re-
vealed that TMEVPG1 activates IFNG by binding to WDR5, 
a component of the histone H3 lysine 4 (H3K4) methyl-
transferase complex, and altering the histone methylation 
level at the IFNG locus [26]. These findings suggest that 
lncRNAs might control T-cell differentiation and suscepti-
bility of pathogens by regulating the abundance of pivotal 
cytokines at the transcriptional level. 
Compared with lncRNAs in T-cells, only a few lncRNAs 
have been reported in B-cell differentiation. One such 
lncRNA is B-cell integration cluster (BIC), a lncRNA that is 
highly expressed in both activated B-cells and T-cells and in 
monocytes/macrophages; however, no evidence of BIC act-
ing as a “long” RNA has been found yet [27]. So far, most 
of the studies on BIC have been focused on its processed 
products, miR-155-5p and miR-155-3p, which play critical 
roles in various physiological and pathological processes, 
such as hematopoietic lineage differentiation, immunity, 
inflammation, and viral infections [28]. Because many 
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functional lncRNAs also contain miRNAs in their exons 
(e.g., H19 [29] and PVT-1 [30]), BIC might be involved in 
hematopoiesis not merely by acting as a host gene of 
miR-155.  
In conclusion, lncRNAs play critical roles in normal 
hematopoiesis by regulating pivotal hematopoietic factors 
or cytokines, which maintain the biology balance and nor-
mal operation of the hematopoietic and immune systems, as 
summarized in Figure 1. Dysregulation of these lncRNAs 
might lead to abnormal hematopoiesis, which results in a 
variety of blood diseases, for example, polycythemia, 
thrombosis, and stroke, by reason of erythropoiesis disorder; 
anemia, including thalassemias and aplastic anemia; and 
malignant hematopoiesis, including multiple myeloma, 
myelodysplasia, and various subtypes of leukemia. 
2  lncRNAs associated with blood diseases in-
teract with crucial susceptibility genes in diffe- 
rent pathways 
Many lncRNAs show cancer-specific expression [2], and 
the biologic features of these lncRNAs suggest that they 
might be involved in the pathogenesis of human diseases. 
Typically, lncRNAs execute molecular functions through 
four major known mechanisms: by acting as signals, decoys, 
guides, or scaffolds [31]. But in all cases, lncRNAs partici-
pate in diseases by mis-regulating target genes or pathways, 
which are essential factors of disease occurrence. 
lncRNAs regulate these genes and pathways either in cis 
or in trans [1,31]. Although it is still controversial whether 
mammalian lncRNAs generally act in cis or in trans, both 
categories of lncRNAs imply a direct influence on target 
genes [1]. The cis-acting lncRNAs are restricted to the site 
of synthesis, and directly influence one or several genes on 
the same chromosome. They are located near disease-  
related genes, which might indicate that they have the po-
tential to serve as disease repressors or therapy targets. By 
contrast, trans-acting lncRNAs diffuse across the whole 
genome and can influence target genes on other chromo-
somes, which might regulate a series of genes in a certain 
pathway. Studies on trans-acting lncRNAs have also pro-
vided an understanding of the possible etiology of human 
diseases. Emerging evidence suggests a number of lncRNAs 
regulate pivotal blood disease-related factors including 
transcriptional factors [12,32], CD antigens [12], and cy-
clin-dependent kinases [33,34], as well as essential hema-
topoietic pathways, both in cis and in trans (Figure 1, right). 
These findings have greatly expanded our knowledge of 
blood development and diseases.  
2.1  lncRNAs interact with HOX gene clusters in ma-
lignant hematopoiesis 
There are a set of genes that are specifically expressed in 
hematopoietic stem cells, progenitors, and mature blood 
cells. One cluster of these genes is the highly conserved 
HOX transcription factor genes [35]. These HOX genes also 
have specific patterns of lineage-restricted expression, 
whereby HOXA genes are expressed in myeloid cells, 
HOXB genes in erythroid cells, and HOXC genes in lym-
phoid cells [35]. Many lncRNAs are located in HOX loci in 
both human and murine, and miRNAs are found to be fre-
quently located inside or near HOX loci with a 15.77 times 
higher incidence rate, as reported in a previous study [36]. 
Although there is no similar report on lncRNAs, numerous 
lncRNAs have been identified in HOX loci, which account 
for a large proportion of the known lncRNAs [37]. More- 
over, some of these HOX-lncRNAs have been found to play 
potent roles by controlling the expression of HOX genes at 
the transcriptional level [12,3840].  
One such example is HOTAIR, a lincRNA located inter-
genic and antisense to the flanking HOXC11 and HOXC12 
genes [41]. Dysregulation of HOTAIR has been shown to 
be involved in a variety of cancers, including breast carci-
noma [42], hepatocellular carcinoma [43,44], colorectal 
cancer [45], and lung cancer [46]. HOTAIR binds to EZH2, 
a component of the H3K27 methylation complex PRC2, 
which leads to the genome-wide re-targeting of the PRC2 
complex, and a 40-kb region of the HOXD locus is tran-
scriptionally silenced by HOTAIR [47]. Another example is 
HOTAIRM1, the myeloid differentiation-related lncRNA 
mentioned above, which is also found to bind with the 
PRC2 complex [22], and which could regulate the expres-
sion of its neighboring HOXA1 gene [12]. Although it is 
still unclear whether the regulation of HOXA1 is performed 
by targeting the PRC2 complex to HOXA1 locus, it is cer-
tain that HOTAIRM1 plays a pivotal role in controlling 
HOXA gene expression. A third murine lncRNA Mira, is 
transcribed from a region between Hoxa6 and Hoxa7, and 
the Mira transcript is required for the recruitment of H3K4 
histone methyltransferase Mll1 to the Mira gene locus and 
the activation of Hoxa6 and Hoxa7 [40]. Interestingly, not 
all HOX-lncRNAs regulate HOX genes by regulating his-
tone methylation. Linc-HOXA1 is a murine lncRNA adja-
cent to Hoxa1, which represses Hoxa1 transcription in cis 
by interacting with PURB, which is an important transcrip-
tional factor during hematopoiesis in murine embryonic 
stem cells [38].  
It is worth noting that HOTAIR restrains the expression 
of HOX genes in trans and Mira activates the HOXA genes 
in cis [40,47], which suggests that these lncRNAs located in 
HOX clusters could control HOX gene expression by dif-
ferent modifications, and that linc-HOXA1 regulates 
HOXA1 expression in a different way [38]. All these re-
searches indicate that HOX-lncRNAs regulate HOX genes 
in a variety of different ways in complicated regulatory 
networks, though most parts of these networks are still un-
known. Among the HOX-lncRNAs, only HOTAIRM1 has 
been proved to participate in hematopoiesis [12]. However, 
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the HOX-lncRNAs that take part in the regulation of HOX 
genes and exhibit expression correlations with their neigh-
boring HOX genes also showed a high probability of being 
involved in blood development [37]. There are still many 
HOX-lncRNAs with unknown functions. Therefore, further 
studies focused on HOX-lncRNAs will help in understand-
ing the complex regulation networks of HOX-lncRNAs and 
HOX genes, as well as functional miRNAs in the HOX lo-
cus, and might provide deeper insights into the mechanisms 
of normal and malignant hematopoiesis. Indeed, it is likely 
that these HOX-related lncRNAs represent useful therapeu-
tic agents and targets for multiple blood diseases.  
2.2  ncRNAs control cell cycle in leukemia 
Cell cycle disorder is one of the most important causes of 
leukemia incidence, and numerous cyclins and cyclin-    
dependent kinases are regarded as vital oncogenes or tumor 
suppressors [4850]. A cell cycle-related lncRNA, ANRIL, 
is located antisense of the INK4b-ARF-INK4a locus, which 
encode three critical cyclin-dependent kinase inhibitors, 
p15INK4b, p14ARF and p16INK4a [16]. The p15INK4b, p14ARF and 
p16INK4a inhibitors are epigenetically silenced in hematopoi-
etic stem cells and play central roles in cell cycle inhibition, 
senescence, differentiation, and stress-induced apoptosis, 
especially in various hematological malignancies [51], and 
the occurrence of p16INK4A/p14ARF/p15INK4b alters the prog-
nosis or disease progression in a variety of leukemia sub-
types [51,52]. For example, deletion of p15 INK4b and p16 
INK4a was reported in acute lymphoblastic leukemia (ALL) 
(>30%) [51] and BCR-ABL-induced leukemia [53]. Intri-
guingly, Iacobucci et al. [54] found a polymorphism in 
ANRIL locus that is associated with BCR-ABL-induced 
ALL, which might be a thread for deregulation of INK4 
locus in some subtypes of leukemia. Furthermore, Yu et al. 
[16] discovered an inverse relation between ANRIL and p15 
expression in leukemia, implying an ANRIL-dependent 
regulation mechanism for p15 in leukemia. This hypothesis 
was supported in subsequent studies. ANRIL was found to 
bind to SUZ12 and CBX7, which are components of PRC1 
and PRC2, respectively, and recruiting these complexes to 
the INK4 locus, which led to the subsequent silencing of 
this gene locus by H3K27-trimethylation [34]. This 
cis-regulation of the INK4 locus by ANRIL might help ex-
plain leukemia pathogenesis, whereby, the over-expression 
of ANRIL epigenetically silenced p14, p15, and p16, which 
are repressors of leukemia, and induced cell cycle disorder, 
differentiation block, and apoptosis arrest in blood cells, 
which lead to the occurrence of leukemia. Further validation 
of this mechanism in hematopoietic cells might provide an 
effective target for the treatment of some leukemia sub-
types. 
ANRIL is the only cell-cycle related lncRNA that has 
been found to be involved in leukemia. However, other 
lncRNAs are known to control the cell cycle in normal so-
matic cells, for example, MALAT1 in diploid fibroblasts 
[55], and lncRNA-LALR1 in hepatocytes [56], and in other 
cancer cells, for example, UCA1 in bladder carcinoma [57], 
and MEG3 in cervical carcinoma [58]. Further screening 
and research on cell-cycle related lncRNAs will also assist 
in targeting therapy in a series of blood diseases, especially 
in leukemias with cell cycle disorder. 
2.3  lncRNAs regulate oncogenes and suppressor genes 
in malignant hematopoiesis 
Malignant hematopoiesis is generally considered to be 
caused by dysregulated expression of oncogenes and tumor 
suppressors. Although the underlying mechanism of these 
abnormal expressions is unclear, lncRNAs might be an ap-
propriate explanation of the problem. P53, which maintains 
genomic integrity and triggers cellular senescence, cell cy-
cle control and apoptosis of damaged cells, is dysregulated 
or mutated in over half of human cancers and about 13% of 
hematological malignancies [59,60]. MEG3, a myelocyte- 
related lncRNA, is highlighted in multiple human malig-
nancies [61] and MEG3 is a lncRNA that regulates p53, 
which might partially explain the aberrations of the p53 
tumor suppressor pathway in some subtypes of malignant 
hematopoiesis. As an important regulator for proper growth 
and development and a putative tumor suppressor, MEG3 
activates p53, inhibits cell proliferation, and might control 
its downstream genes by recruiting the PRC2 complex and 
epigenetically repressing gene expression levels [62]. 
MEG3 was found to display aberrant hypermethylation in 
its promoter region in nearly half of a cohort of 85 MDS 
and AML patients [19]. Another independent assessment of 
40 AML samples also confirmed the aberrant methylations 
[18]. The hypermethylation of the MEG3 promoter also 
correlates with decreased overall survival, which can serve 
as a prognosis marker in myeloid malignancies [19]. Be-
cause AML is a heterogeneous group of genetically and 
phenotypically aggressive disorders in which the differenti-
ation of hematopoietic progenitor cells is blocked, it is 
highly probable that MEG3 plays an important role in mye-
loid differentiation. It is reasonable to assume that the in-
teractions of MEG3 with MDM2, p53, GDF15, and p16 in 
other cancers will likely demonstrate a role for MEG3 that 
is similar to its role in leukemia [63]. These proposals need 
further experimental validations.  
The proto-oncogene MYC is another important gene in-
volved in malignant hematopoiesis. MYC plays a pivotal 
role in cell cycle regulation, metabolism, apoptosis, differ-
entiation, cell adhesion, and tumorigenesis, and participates 
in regulating hematopoietic homeostasis [64]. lncRNA 
PVT-1 is adjacent to the MYC gene locus and is frequently 
involved in the translocations that occur in about 20% of 
Burkitt’s lymphoma and 16% of multiple myeloma, as well 
as in most murine plasmacytomas [30,65,66]. Apart from 
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forming fusion genes, PVT-1 is suggested to be a MYC ac-
tivator, and has also been proved to be regulated by MYC, 
which implies a feedback regulation mechanism [66]. Alt-
hough details of the interaction between PVT-1 and MYC 
remain unrevealed, further investigation of this mechanism 
might provide a powerful therapy approach for malignant 
hematopoiesis. 
In addition to the single genes, some relevant pathways 
are also involved in hematological malignancies. One ex-
ample is the NF-B signaling pathway, which is centrally 
involved in the homeostasis of the hematopoietic system 
where it is induced in inflammation and inhibits apoptosis, 
and is activated in chronic lymphocytic leukemia (CLL) 
[67]. A recent study reported that two lncRNAs, DLEU1 
and DLEU2, map to a critical region that is recurrently de-
leted in CLL [67]. In CLL patients, substantial DNA-   
demethylation and enriched histone H3K4 methylation at 
the transcriptional start sites of DLEU1 and DLEU2 were 
found. These two lncRNAs might control a series of genes 
in the NF-B pathway, either by inducing or repressing the 
pathway activity, implying that DLEU1 and DLEU2 exert a 
precise and complicated NF-B pathway regulating mecha-
nism [67]. In brief, some lncRNAs regulate pivotal onco-
genes, tumor suppressors or relevant pathways in malignant 
hematopoiesis, which suggests an important focus of further 
study, even though, at present, little is known about these 
mechanisms. 
2.4  lncRNAs interact with imprinted genes in hemato-
logical malignancies 
Abnormal imprinting is also an important pathogenesis in 
many blood diseases [68,69]. One of the earliest described 
lncRNAs, H19, is involved in imprinting regulation of its 
neighboring gene IGF2, as well as in trans-regulation of a 
group of imprinted genes, including Igf2r and Dlk1 [70,71], 
suggesting an important role for H19 in genomic imprinting 
during growth and development. H19 is considered to be an 
oncogene or tumor suppressor in different cancers [7174]. 
In malignant hematopoiesis, expression of H19 is reduced 
in AML and CML [75,76], as well as in chronic MDS [75]. 
Loss of imprinting at the H19 locus that results in high H19 
expression was found in adult T-cell leukemia and lym-
phoma patients [77], suggesting that H19 plays disparate 
roles in different leukemia subtypes. Accumulating evi-
dence suggests that H19 could bind PRC2 [62] and Igf2 
mRNA binding-protein 1 (IMP1) [78], which could regulate 
gene expression levels by both chromatin remodeling and 
post-transcriptional processes. Moreover, H19 also contains 
the precursor of miR-675 in exon one [29], suggesting that 
H19 might serve as a bi-functional RNA which can act ei-
ther as a miRNA or an lncRNA in different regulation 
pathways and cell contexts. This makes the regulation 
mechanism of H19 more complicated, and might help to 
explain the conflicting reports that it acts as both a tumor 
suppressor and oncogene in malignant hematopoiesis. Be-
cause of its widespread and complicated roles in blood dis-
ease, further research to identify how H19 functions as a 
full-length lncRNA or miR-675 in different cell contexts 
might reveal the underlying mechanisms of H19 regulation. 
Further identification of target genes of both lncRNA H19 
and miR-675 in malignant hematopoiesis could also provide 
potential specific therapeutic targets for different subtypes 
of leukemia. In addition, H19 is regarded as a prognosis 
marker in multiple cancers [73,74,79,80], and the prognos-
tic implication of H19 in blood disease is also worth ex-
ploring to develop lncRNA-based diagnosis and lncRNA- 
mediated therapy.  
2.5  lncRNAs associated with X-chromosome inactiva-
tion in hematological malignancies  
A large number of lncRNAs are located in the X chromo-
some and participate in X chromosome inactivation, in-
cluding XIST, TSIX, JPX, and XITE [1]. These X chromo-
some-inactive related lncRNAs silence gene expression by 
the epigenetic modification of histones and DNA in a com-
plicated interaction model. X chromosome aneuploidies, on 
the other hand, have long been associated with human can-
cers, but the causality was not established until recently [17]. 
Yildirim et al. [17] deleted Xist in the blood of mice and 
demonstrated that mutant females develop a highly aggres-
sive myeloproliferative neoplasm and MDS with 100% 
penetrance, which suggested that Xist loss results in X reac-
tivation and induces significantly higher abundance of 
X-linked genes, including some oncogenes. Thus, it was 
confirmed that Xist is required not only to maintain X 
chromosome inactivation, but is also necessary in suppress-
ing cancer in vivo. Although no studies on other X chromo-
some-inactive-related lncRNAs in blood diseases have been 
performed, because abnormal X chromosome inactivation 
might cause various blood diseases, it is possible that these 
X chromosome-inactive-related lncRNAs might also be 
involved in blood disease suppressing.  
To summarize, a great many nonprotein-coding tran-
scripts that are relevant in normal and malignant hemato-
poiesis have been found to regulate their target genes by 
RNA interference or silencing at the chromatin level, as 
depicted in Figure 1. However, our knowledge of these 
lncRNAs is just the tip of the iceberg; thus, further research 
and information mining about these lncRNAs are still re-
quired. 
3  Genome identification of lncRNAs might 
provide new targets for blood diseases 
High-throughput sequencing and microarray analysis have 
provided powerful tools to obtain global cell transcriptome 
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profiles, which can be used to screen potential lncRNAs 
with physiological functions in the biology of blood diseas-
es [81,82]. These genomic studies will also provide data-
bases for further functional studies. A transcriptome se-
quencing study of the Sezary syndrome, one of the most 
common forms of cutaneous T-cell lymphoma, was per-
formed recently by Lee et al. [83]. Thirteen unannotated 
lncRNAs were found to be differentially expressed in 
Sezary syndrome. The functional annotation of these Sezary 
syndrome-associated lncRNAs will provide further insights 
into the mechanisms of Sezary syndrome pathogeny. Alt-
hough only a small number of genome-wide studies of this 
type have been performed till now, such studies may detect 
potent lncRNAs involved in leukemia classification and 
therapy. 
Another class of genome-wide studies on lncRNAs is the 
screening of DNA and histone modifications, and transcrip-
tion factor binding sites by chromatin immunoprecipitation 
followed by sequencing (ChIP-seq), which has provided the 
modification profiles of lncRNAs [81,84]. These data have 
contributed to in-depth knowledge of the spatiotemporal 
expression pattern of lncRNAs, which has provided further 
clues and evidence for understanding the function of blood 
disease-specific lncRNAs. Although some ChIP-seq data 
for blood cell lines have been provided by the ENCODE 
project [85], ChIP-seq of patients with blood diseases and of 
cells under different treatments are still important for 
lncRNA screening. In addition, the re-analysis of previous 
ChIP-seq data that were focused on mRNAs may also help 
in identifying lncRNAs associated with various blood dis-
eases. 
A third class of genome-wide studies is RNA immuno-
precipitation followed by sequencing (RIP-seq) [62]. Many 
lncRNAs bind to protein complexes, therefore, the RIP-seq 
studies on different cells could indicate potential functions 
of lncRNAs that bind with known complexes. A combined 
analysis of RNA expression data and ChIP-seq data might 
help define the function of some lncRNAs. Genome-wide 
data provides the opportunity for researchers to select piv-
otal lncRNAs in blood disease, and to predict the potent 
functional mechanism of these lncRNAs. Thus far, only a 
few genome-wide lncRNA studies on blood disease have 
been performed and future genome-wide research on 
lncRNAs would help to explain the mechanisms of 
lncRNAs, which may contribute to the diagnosis and treat-
ment of blood diseases.  
4  Conclusion and perspectives 
Emerging studies have defined lncRNAs as an important 
aspect of development, and accumulating evidence suggests 
that lncRNAs play central roles in hematopoiesis; however, 
the mechanisms of action of the majority of lncRNAs in 
normal and malignant hematopoiesis are still unclear. Fu-
ture genome-wide screening and in-depth functional studies 
on the lncRNAs are urgently needed to provide insights into 
the interaction networks of lncRNAs, mRNAs, and miR-
NAs in the biology of normal and malignant hematopoiesis. 
Such studies might offer powerful clinical tools and novel 
molecular strategies for blood disease diagnosis, prognosis 
and therapy. 
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